A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Placebo
50 mg SP2086
100 mg SP2086
200 mg SP2086
100 mg Sitagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Sp2086, Phase II, monotherapy
Eligibility Criteria
Inclusion Criteria:
- 20 Years to 70 Years ,Male and Female diagnosed with type 2 diabetes mellitus
- Patients not on an oral antihyperglycemic agent (OHA) with 7.0% ≤HbA1C ≤10.5%,or not on an OHA for 3 months with 7.0% ≤HbA1C ≤10.5%
- BMI 19~35 kg/m2
Exclusion Criteria:
- Patient has history of type 1 diabetes mellitus
- Patient has history of ketoacidosis
- Patient has history of severe unconscious hypoglycemosis
- Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis
- Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical
- Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg
- Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL);total bilirubin >2×UNL; creatinine>1.5 mg/dL (Male,132.6μmol/L) ,>1.4 mg/dL(Female,123.8μmol/L)
- Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery
- Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. )
- Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on
- Patient has history of malignancy
- Patient has history of alcohol or drug abuse
Sites / Locations
- Chinese PLA General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Active Comparator
Arm Label
Placebo
50 mg SP2086
100 mg SP2086
200 mg SP2086
100 mg Sitagliptin
Arm Description
Outcomes
Primary Outcome Measures
the change from baseline in HbA1c at 12 week
Secondary Outcome Measures
Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels
Change From Baseline in Fasting Plasma Glucose at Week 4, 8 and 12
Post-meal total and incremental glucose,insulin and C-peptide area under the curve at week 4 ,12
Change from baseline in Homeostasis model assessment-beta(HOMA-β) at week 4,week12
Change From Baseline in lipid at Week 4, 8 and 12
Change From Baseline in Body Weight at Week 4,8,12
Full Information
NCT ID
NCT01969357
First Posted
October 17, 2013
Last Updated
October 21, 2013
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT01969357
Brief Title
A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
Official Title
A Multicenter Randomized, Double-blind, Placebo and Positive Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients
Study Type
Interventional
2. Study Status
Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
June 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the effective dose range of SP2086 in Patients with type 2 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
Sp2086, Phase II, monotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
50 mg SP2086
Arm Type
Experimental
Arm Title
100 mg SP2086
Arm Type
Experimental
Arm Title
200 mg SP2086
Arm Type
Experimental
Arm Title
100 mg Sitagliptin
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Tablets(n=4),once daily for 84 days
Intervention Type
Drug
Intervention Name(s)
50 mg SP2086
Intervention Description
Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
Intervention Type
Drug
Intervention Name(s)
100 mg SP2086
Intervention Description
Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
Intervention Type
Drug
Intervention Name(s)
200 mg SP2086
Intervention Description
Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
Intervention Type
Drug
Intervention Name(s)
100 mg Sitagliptin
Intervention Description
Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
Primary Outcome Measure Information:
Title
the change from baseline in HbA1c at 12 week
Time Frame
baseline, week 12
Secondary Outcome Measure Information:
Title
Percentage of Participants Achieving Less Than (<) 6.5% or <7% HbA1c Levels
Time Frame
week 12
Title
Change From Baseline in Fasting Plasma Glucose at Week 4, 8 and 12
Time Frame
Baseline, Week 4, 8, 12
Title
Post-meal total and incremental glucose,insulin and C-peptide area under the curve at week 4 ,12
Time Frame
baseline, week 4 ,12
Title
Change from baseline in Homeostasis model assessment-beta(HOMA-β) at week 4,week12
Time Frame
baseline, week 4,12week
Title
Change From Baseline in lipid at Week 4, 8 and 12
Time Frame
baseline, week 4, 8, 12
Title
Change From Baseline in Body Weight at Week 4,8,12
Time Frame
baseline, Week 4, 8,12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
20 Years to 70 Years ,Male and Female diagnosed with type 2 diabetes mellitus
Patients not on an oral antihyperglycemic agent (OHA) with 7.0% ≤HbA1C ≤10.5%,or not on an OHA for 3 months with 7.0% ≤HbA1C ≤10.5%
BMI 19~35 kg/m2
Exclusion Criteria:
Patient has history of type 1 diabetes mellitus
Patient has history of ketoacidosis
Patient has history of severe unconscious hypoglycemosis
Patient has history of acute and chronic pancreatitis or pancreatic injury that may lead to high risk of pancreatitis
Patient has history of decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, persistence and clinical
Patient has history of a history of hypertension, and after antihypertensive treatment, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg
Patient has severe liver or kidney disease,alanine aminotransferase >2×UNL, Aspartate Aminotransferase >2×upper normal limit(UNL);total bilirubin >2×UNL; creatinine>1.5 mg/dL (Male,132.6μmol/L) ,>1.4 mg/dL(Female,123.8μmol/L)
Patient has severe chronic gastrointestinal disease or therapy that may affect drug absorption, such as gastrointestinal surgery
Patient has severe haematological diseases or other diseases leading to hemolyze and red blood cell unstable (malaria、haemolytic anaemia eg. )
Patient has other endocrine diseases, for example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia and so on
Patient has history of malignancy
Patient has history of alcohol or drug abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Changyu Pan, M.D.
Organizational Affiliation
Chinese PLA General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chinese PLA General Hospital
City
Beijing
Country
China
12. IPD Sharing Statement
Learn more about this trial
A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
We'll reach out to this number within 24 hrs